Висока важливість
16 вер. 2026 р.
To assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the investigational drug ALN-6400 in both healthy volunteers and adult patients diagnosed with Hereditary Haemorrhagic Telangiectasia (HHT).
The study will employ a two-part design: initially administering single ascending doses of ALN-6400 to healthy volunteers followed by multiple-dose evaluations in patients with HHT. Safety and tolerability will be systematically monitored alongside pharmacokinetic and pharmacodynamic assessments.
Initial findings will provide data on the drug's safety profile and tolerability, while efficacy in HHT patients will be determined through PD responses and symptom assessments related to arteriovenous malformations (AVMs) commonly seen in HHT.
The study's limitations may include a small sample size, reliance on short-term observation for efficacy outcomes, and variability in patient responses due to the heterogeneous nature of HHT's clinical presentation.
Understanding the safety and efficacy of ALN-6400 could significantly impact the management of HHT, a condition with limited therapeutic options. If successful, it may offer a new avenue for mitigating complications such as AVMs, ultimately improving patient outcomes in this underserved population.
Показано англійською
The purpose of this study is to: * evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers * evaluate the efficacy, safety, tolerability and PD of multiple doses of ALN-6400 in adult patients with HHT